We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Visa, Charter, Biogen, BP and BB&T
Read MoreHide Full Article
For Immediate Release
Chicago, IL –February 11, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Visa (V - Free Report) , Charter Communications (CHTR - Free Report) , Biogen (BIIB - Free Report) , BP plc (BP - Free Report) and BB&T .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Visa, Charter Communications and Biogen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa, Charter Communications and Biogen. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Visa’s shares have outperformed the Zacks Financial Transaction Services industry over the past year (+20.5% vs. +16%). Visa’s first-quarter fiscal 2019 earnings beat expectations and increased year over year. The results were driven by growth in payments volume, cross-border volume and processed transactions, and a lower tax rate.
The Zacks analyst thinks Visa’s strategic acquisitions and alliances, technology upgrades and effective marketing have paved the way for long-term growth and consistent increase in revenues. Visa is well poised to gain from growing electronic payment processing and a solid brand name. Its strong capital position enables investments in business.
Nevertheless, high client incentives and operating expenses, and foreign exchange volatility might put pressure on margins. Softness in cross border volumes is another concern.
Shares of Charter Communications have outperformed the Zacks Cable TV industry over the past year (-1.4% vs. -5.1%). Charter’s fourth-quarter 2018 revenues increased on growth in Internet, video, advertising and commercial revenues. Growth in Internet customers and rate adjustments aided Internet revenues in the reported quarter.
Additionally, Charter’s Spectrum Internet Gig service, which uses DOCSIS 3.1 technology, is available across its entire footprint. The Zacks analyst thinks this service, which provides enhanced Internet speed is expected to further boost subscriber growth. Moreover, Charter’s All Digital initiative, which will help the company offer advanced products and services and enhance video picture quality is now complete across its entire residential and business footprint.
However, Charter’s bottom line suffered due to higher interest expense. The company continues to struggle in a saturated and competitive multi-channel U.S. video market.
Biogen’s shares have outperformed the Zacks Biomedical and Genetics industry in the past year (-2.5% vs. -17.1%). Biogen beat estimates for earnings and sales in Q4. Biogen has a strong position in the MS market. The Zacks analyst likes the company’s efforts to diversify beyond MS to other areas like Alzheimer’s, Parkinson's and stroke among others.
Meanwhile, its newest drug Spinraza is performing well and has multi-billion dollar potential. Biogen’s efforts to regularly in-license assets to build its pipeline are encouraging since several of them have transformative potential. Several data readouts are expected in 2019 with multiple potential launches in the early 2020s.
However, its core MS business, excluding Ocrevus royalties, has been largely flat. Also, potential competition to Spinraza from competitors’ gene therapy programs for SMA is a concern. Though Biogen’s CNS pipeline is attractive, it is a high-risk area.
Other noteworthy reports we are featuring today include BP plc and BB&T.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Visa, Charter, Biogen, BP and BB&T
For Immediate Release
Chicago, IL –February 11, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Visa (V - Free Report) , Charter Communications (CHTR - Free Report) , Biogen (BIIB - Free Report) , BP plc (BP - Free Report) and BB&T .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Visa, Charter Communications and Biogen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa, Charter Communications and Biogen. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Visa’s shares have outperformed the Zacks Financial Transaction Services industry over the past year (+20.5% vs. +16%). Visa’s first-quarter fiscal 2019 earnings beat expectations and increased year over year. The results were driven by growth in payments volume, cross-border volume and processed transactions, and a lower tax rate.
The Zacks analyst thinks Visa’s strategic acquisitions and alliances, technology upgrades and effective marketing have paved the way for long-term growth and consistent increase in revenues. Visa is well poised to gain from growing electronic payment processing and a solid brand name. Its strong capital position enables investments in business.
Nevertheless, high client incentives and operating expenses, and foreign exchange volatility might put pressure on margins. Softness in cross border volumes is another concern.
(You can read the full research report on Visa here >>>).
Shares of Charter Communications have outperformed the Zacks Cable TV industry over the past year (-1.4% vs. -5.1%). Charter’s fourth-quarter 2018 revenues increased on growth in Internet, video, advertising and commercial revenues. Growth in Internet customers and rate adjustments aided Internet revenues in the reported quarter.
Additionally, Charter’s Spectrum Internet Gig service, which uses DOCSIS 3.1 technology, is available across its entire footprint. The Zacks analyst thinks this service, which provides enhanced Internet speed is expected to further boost subscriber growth. Moreover, Charter’s All Digital initiative, which will help the company offer advanced products and services and enhance video picture quality is now complete across its entire residential and business footprint.
However, Charter’s bottom line suffered due to higher interest expense. The company continues to struggle in a saturated and competitive multi-channel U.S. video market.
(You can read the full research report on Charter Communications here >>>).
Biogen’s shares have outperformed the Zacks Biomedical and Genetics industry in the past year (-2.5% vs. -17.1%). Biogen beat estimates for earnings and sales in Q4. Biogen has a strong position in the MS market. The Zacks analyst likes the company’s efforts to diversify beyond MS to other areas like Alzheimer’s, Parkinson's and stroke among others.
Meanwhile, its newest drug Spinraza is performing well and has multi-billion dollar potential. Biogen’s efforts to regularly in-license assets to build its pipeline are encouraging since several of them have transformative potential. Several data readouts are expected in 2019 with multiple potential launches in the early 2020s.
However, its core MS business, excluding Ocrevus royalties, has been largely flat. Also, potential competition to Spinraza from competitors’ gene therapy programs for SMA is a concern. Though Biogen’s CNS pipeline is attractive, it is a high-risk area.
(You can read the full research report on Biogen here >>>).
Other noteworthy reports we are featuring today include BP plc and BB&T.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.